cloudfront
  • info@reportsandmarkets.com
  • +44-020-3286-9338 (UK) | +1-214-736-7666 (US) | +1-740-994-0111 (US)
  • Sign In
  • Register

Report Detail



Pharma & HealthcareGlobal Drugs for Rheumatoid Arthritis Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • RnM2541266
  • |
  • 5 November, 2018
  • |
  • Global
  • |
  • 115 pages
  • |
  • GIR (Global Info Research)
  • |
  • Pharma & Healthcare

Rheumatoid arthritis can be difficult to diagnose in its early stages because the early signs and symptoms mimic those of many other diseases. There is no one blood test or physical finding to confirm the diagnosis.

Scope of the Report:

The worldwide market for Drugs for Rheumatoid Arthritis is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

This report focuses on the Drugs for Rheumatoid Arthritis in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers

AbbVie Inc

Hoffman-La Roche AG

Amgen Inc

Pfizer Inc

Bristol-Myers Squibb Co

Johnson & Johnson

UCB Biosciences Inc

Mitsubishi Tanabe Pharma Corp

Biogen Inc

Merck & Co

Market Segment by Product Type

Pharmaceuticals

Biopharmaceuticals

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Prescription

OTC

Market Segment by Applications, can be divided into

Hospital

Clinics

Other

There are 15 Chapters to deeply display the global Drugs for Rheumatoid Arthritis market.

Chapter 1, to describe Drugs for Rheumatoid Arthritis Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Drugs for Rheumatoid Arthritis, with sales, revenue, and price of Drugs for Rheumatoid Arthritis, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Drugs for Rheumatoid Arthritis, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Drugs for Rheumatoid Arthritis market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Drugs for Rheumatoid Arthritis sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source


Table of Contents

1 Market Overview

1.1 Drugs for Rheumatoid Arthritis Introduction

1.2 Market Analysis by Type

1.2.1 Prescription

1.2.2 OTC

1.3 Market Analysis by Applications

1.3.1 Hospital

1.3.2 Clinics

1.3.3 Other

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 AbbVie Inc

2.1.1 Business Overview

2.1.2 Drugs for Rheumatoid Arthritis Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 AbbVie Inc Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Hoffman-La Roche AG

2.2.1 Business Overview

2.2.2 Drugs for Rheumatoid Arthritis Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Hoffman-La Roche AG Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Amgen Inc

2.3.1 Business Overview

2.3.2 Drugs for Rheumatoid Arthritis Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Amgen Inc Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Pfizer Inc

2.4.1 Business Overview

2.4.2 Drugs for Rheumatoid Arthritis Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Pfizer Inc Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 Bristol-Myers Squibb Co

2.5.1 Business Overview

2.5.2 Drugs for Rheumatoid Arthritis Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Bristol-Myers Squibb Co Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6 Johnson & Johnson

2.6.1 Business Overview

2.6.2 Drugs for Rheumatoid Arthritis Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Johnson & Johnson Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7 UCB Biosciences Inc

2.7.1 Business Overview

2.7.2 Drugs for Rheumatoid Arthritis Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 UCB Biosciences Inc Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.8 Mitsubishi Tanabe Pharma Corp

2.8.1 Business Overview

2.8.2 Drugs for Rheumatoid Arthritis Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Mitsubishi Tanabe Pharma Corp Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.9 Biogen Inc

2.9.1 Business Overview

2.9.2 Drugs for Rheumatoid Arthritis Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Biogen Inc Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.10 Merck & Co

2.10.1 Business Overview

2.10.2 Drugs for Rheumatoid Arthritis Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Merck & Co Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.11 Market Segment by Product Type

2.11.1 Business Overview

2.11.2 Drugs for Rheumatoid Arthritis Type and Applications

2.11.2.1 Product A

2.11.2.2 Product B

2.11.3 Market Segment by Product Type Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.12 Pharmaceuticals

2.12.1 Business Overview

2.12.2 Drugs for Rheumatoid Arthritis Type and Applications

2.12.2.1 Product A

2.12.2.2 Product B

2.12.3 Pharmaceuticals Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.13 Biopharmaceuticals

2.13.1 Business Overview

2.13.2 Drugs for Rheumatoid Arthritis Type and Applications

2.13.2.1 Product A

2.13.2.2 Product B

2.13.3 Biopharmaceuticals Drugs for Rheumatoid Arthritis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Drugs for Rheumatoid Arthritis Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Drugs for Rheumatoid Arthritis Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Drugs for Rheumatoid Arthritis Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Drugs for Rheumatoid Arthritis Manufacturer Market Share in 2017

3.3.2 Top 6 Drugs for Rheumatoid Arthritis Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Drugs for Rheumatoid Arthritis Market Analysis by Regions

4.1 Global Drugs for Rheumatoid Arthritis Sales, Revenue and Market Share by Regions

4.1.1 Global Drugs for Rheumatoid Arthritis Sales and Market Share by Regions (2013-2018)

4.1.2 Global Drugs for Rheumatoid Arthritis Revenue and Market Share by Regions (2013-2018)

4.2 North America Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

4.3 Europe Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

4.5 South America Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

5 North America Drugs for Rheumatoid Arthritis by Countries

5.1 North America Drugs for Rheumatoid Arthritis Sales, Revenue and Market Share by Countries

5.1.1 North America Drugs for Rheumatoid Arthritis Sales and Market Share by Countries (2013-2018)

5.1.2 North America Drugs for Rheumatoid Arthritis Revenue and Market Share by Countries (2013-2018)

5.2 United States Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

5.3 Canada Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

5.4 Mexico Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

6 Europe Drugs for Rheumatoid Arthritis by Countries

6.1 Europe Drugs for Rheumatoid Arthritis Sales, Revenue and Market Share by Countries

6.1.1 Europe Drugs for Rheumatoid Arthritis Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Drugs for Rheumatoid Arthritis Revenue and Market Share by Countries (2013-2018)

6.2 Germany Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

6.3 UK Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

6.4 France Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

6.5 Russia Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

6.6 Italy Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

7 Asia-Pacific Drugs for Rheumatoid Arthritis by Countries

7.1 Asia-Pacific Drugs for Rheumatoid Arthritis Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Drugs for Rheumatoid Arthritis Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Drugs for Rheumatoid Arthritis Revenue and Market Share by Countries (2013-2018)

7.2 China Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

7.3 Japan Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

7.4 Korea Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

7.5 India Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

8 South America Drugs for Rheumatoid Arthritis by Countries

8.1 South America Drugs for Rheumatoid Arthritis Sales, Revenue and Market Share by Countries

8.1.1 South America Drugs for Rheumatoid Arthritis Sales and Market Share by Countries (2013-2018)

8.1.2 South America Drugs for Rheumatoid Arthritis Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

8.3 Argentina Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

8.4 Colombia Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

9 Middle East and Africa Drugs for Rheumatoid Arthritis by Countries

9.1 Middle East and Africa Drugs for Rheumatoid Arthritis Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Drugs for Rheumatoid Arthritis Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Drugs for Rheumatoid Arthritis Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

9.3 UAE Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

9.4 Egypt Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

9.5 Nigeria Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

9.6 South Africa Drugs for Rheumatoid Arthritis Sales and Growth Rate (2013-2018)

10 Global Drugs for Rheumatoid Arthritis Market Segment by Type

10.1 Global Drugs for Rheumatoid Arthritis Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Drugs for Rheumatoid Arthritis Sales and Market Share by Type (2013-2018)

10.1.2 Global Drugs for Rheumatoid Arthritis Revenue and Market Share by Type (2013-2018)

10.2 Prescription Sales Growth and Price

10.2.1 Global Prescription Sales Growth (2013-2018)

10.2.2 Global Prescription Price (2013-2018)

10.3 OTC Sales Growth and Price

10.3.1 Global OTC Sales Growth (2013-2018)

10.3.2 Global OTC Price (2013-2018)

11 Global Drugs for Rheumatoid Arthritis Market Segment by Application

11.1 Global Drugs for Rheumatoid Arthritis Sales Market Share by Application (2013-2018)

11.2 Hospital Sales Growth (2013-2018)

11.3 Clinics Sales Growth (2013-2018)

11.4 Other Sales Growth (2013-2018)

12 Drugs for Rheumatoid Arthritis Market Forecast (2018-2023)

12.1 Global Drugs for Rheumatoid Arthritis Sales, Revenue and Growth Rate (2018-2023)

12.2 Drugs for Rheumatoid Arthritis Market Forecast by Regions (2018-2023)

12.2.1 North America Drugs for Rheumatoid Arthritis Market Forecast (2018-2023)

12.2.2 Europe Drugs for Rheumatoid Arthritis Market Forecast (2018-2023)

12.2.3 Asia-Pacific Drugs for Rheumatoid Arthritis Market Forecast (2018-2023)

12.2.4 South America Drugs for Rheumatoid Arthritis Market Forecast (2018-2023)

12.2.5 Middle East and Africa Drugs for Rheumatoid Arthritis Market Forecast (2018-2023)

12.3 Drugs for Rheumatoid Arthritis Market Forecast by Type (2018-2023)

12.3.1 Global Drugs for Rheumatoid Arthritis Sales Forecast by Type (2018-2023)

12.3.2 Global Drugs for Rheumatoid Arthritis Market Share Forecast by Type (2018-2023)

12.4 Drugs for Rheumatoid Arthritis Market Forecast by Application (2018-2023)

12.4.1 Global Drugs for Rheumatoid Arthritis Sales Forecast by Application (2018-2023)

12.4.2 Global Drugs for Rheumatoid Arthritis Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source


captcha
Enter the code in the box:


captcha
Enter the code in the box:

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may not print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.


captcha
Enter the code in the box:



Summary:
Get latest Market Research Reports on Drugs for Rheumatoid Arthritis . Industry analysis & Market Report on Drugs for Rheumatoid Arthritis is a syndicated market report, published as Global Drugs for Rheumatoid Arthritis Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023. It is complete Research Study and Industry Analysis of Drugs for Rheumatoid Arthritis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,480.00
$5,220.00
$6,960.00
2,336.82
3,505.23
4,673.64
3,202.30
4,803.44
6,404.59
421,567.20
632,350.80
843,134.40
230,770.63
346,155.95
461,541.26
Add To Cart Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report